How to Treat Renal Cell Carcinoma (RCC) in 2026 – Dr. Katy Beckermann

Welcome back to the Oncology Brothers podcast! In this episode, we discussed current treatment landscape and updates from GU ASCO 2026, with focus on kidney cancer.

Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

• ⁠X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

We were joined by Dr. Katy Beckermann, a medical oncologist from Tennessee Oncology, to discuss:

• The current standard of care for renal cell carcinoma (RCC), including adjuvant treatment options post-surgery.
• The implications of the KEYNOTE-564 study and the approval of Pembrolizumab for high-risk RCC patients.
• Insights from the LITESPARK- 022 trial, comparing Pembrolizumab with the combination of Pembrolizumab and Belzutifan in the adjuvant setting.
• The challenges of undertreatment versus overtreatment in kidney cancer therapy, including side effects and financial toxicity.
• Strategies for managing metastatic disease, including re-challenging immunotherapy and the role of IMDC criteria in treatment decisions.
• The promising data from LITESPARK-011, exploring the combination of Lenvatinib and Belzutifan in the second-line setting.

Tune in for an informative discussion that covers the latest research, clinical practices, and expert opinions in the field of kidney cancer. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology!

#KidneyCancer, #RenalCellCarcinoma, #GUASCO2026, #OncBrothers